COVID 19 Enfeksiyon Tedavisi
Synopsis
COVID-19 is a contagious viral infection caused by the SARS-CoV-2 agent through cell membrane fusion via ACE-2 receptors, which was declared a pandemic by the World Health Organization in March 2020. In the acute phase of the disease, which is transmitted via droplets, a decrease in lymphocyte count accompanied by elevated levels of CRP, IL-6, Ferritin, and D-dimer serve as reliable indicators of poor prognosis and severe clinical condition. Clinically, 80% of cases manifest a mild course, 15% present with pneumonia, and approximately 5% develop critical conditions such as Acute Respiratory Distress Syndrome (ARDS), septic shock, and multiple organ failure. In the treatment approach, Hydroxychloroquine and Favipiravir, which inhibit viral entry and replication, stand out as primary antiviral options, while Lopinavir/ritonavir is considered a safe alternative for pregnant patients. Against cytokine storm and macrophage activation syndrome that may develop around days 7–8 of infection, anti-cytokine therapies such as Tocilizumab and Anakinra (IL-6 and IL-1 receptor antagonists), as well as immune plasma transfusion and stem cell therapies, are utilized. In hypoxic patients and severe pneumonia cases, corticosteroids such as pulse methylprednisolone are administered to control inflammation, while prophylactic anticoagulation with low molecular weight heparin is provided to prevent increased thromboembolism risk. For critical cases with worsening respiratory distress, advanced respiratory support methods including noninvasive or invasive mechanical ventilation and ECMO play a vital role.
References
Dashraath P, Wong J.L, Lim M.X, et al. Coronavirus disease 2019(COVID 19) pandemic and pregnancy. American Journal Of Obstetrics and Gynecology. 2020;222:521-531
Kannan S, Sheeza A, Hemalatha K, et al.COVID-19(Novel Coronavirüs 2019)-recent trends. European Rewiev for Medical and Pharmacological Sciences. 2020;24:2006-2011
Shi Y, Tan M, Chen X, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Preprint at medRxiv 2020; Doi:10.1101/2020.03.12.20034736
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratorydistress syndrome. Lancet Respir.Med. 2020;8:420-422
Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019(COVID-19)in Wuhan, China. Clinical Infectious Diseases 2020;71:762-768. Doi:10.1093/cid/ciaa248
Clerkin K, Fried J.A, Raikhelkar J, et al. COVID19 and Cardiovascular Disease. Circulation, 2020;141:1648-1655. Doi:10.1161/CIRCULATIONAHA.120.046941 DRUG
Khuroo M.S. Chloroquine and hydroxychloroquine in Coronavirus disease 2019(COVID-19). Facts, fiction and the hype: a critical appraisal. International Journal of Antimicrobial Agents, 2020;56:106101. Doi:10. 1016/j.ijantimicag.2020.106101
Batırel A. COVID-19 un özgün tedavisi. South Clin. İst. Euras, 2020;31:31-41. Doi:10,14744/scei2020,57704
Janssen N, Genta M. The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy and lactation. Arch Intern Med, 2000;160:610-19
Biot C, Daher W, Chavain N, et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006;49:2845–49
Yao X, Ye F, Zhang M et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; PMID: 32150618.
T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü COVID-19(SARS-CoV-2 Enfeksiyonu) Rehberi. Bilim Kurulu Çalışması. Ankara; 14 Nisan 2020.
Abdel-Hamid H, Oddis CV, Lacomis D.Severe Hydroxychloroquine myopathy. Muscle Nerve, 2008; 38:1206-1210
Jorge A, Ung C, Young LH, et al. Hydroxychloroquineretinopathy-implications of research advances for rheumatology care. Nat Rev Rheumatol, 2018;14:693-703
Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering, 2020;6:1192-1198. Doi: 10.1016/j.eng2020.03.007
Atak Y, Bayrakal V, Baskın H.Sitokin Fırtınası ve Covid-19. İmmunoloji ve Covid-19 Türkiye Klinikleri, 2020;1:15-21
Çelikel B. Cytokine Release Syndrome and Treatment in COVID-19. Türkiye Çocuk Hastalıkları Dergisi. 2020;14:55-59. Doi: 10.12956/tchd.757711
Guaraldi G, Meschiari M, Milic J, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology, 2020;2:474-484. Doi: 10.1016/S2665-9913(20)30173-9
Xu X, Han M, Li T, et al. Effective treatment of severe COVID 19 patients with tocilizumab. PNAS, 2020;117: 10970-10975. Doi: 10.1073/pnas.2005615117
Peterson D, Damsky W, King B, et al. The use of januse kinase inhibitors in the time of SARS-CoV-2. J Am Acad Dermatol. 2020; 82:223-226
Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically ILL PatientsWith COVID-19 With Convalescent Plasma. JAMA. 2020;323:1582-1589. Doi: 10,1001/jama.2020.4783
Zhan W.Q, Li M.D, Xu M, et al. Successful treatment of COVID-19 using extracorporeal membrane oxygenation, a case report. European Review for Medical and Pharmacological Sciences. 2020;24:3385-3389
Pfefferbaum B, North C. Mental Health and the Covid-19 Pandemic. N engl J Med. 2020;383:510-512. Doi:10.1056/NEJMp2008017